Evidence map›Paper›PMID 40584967›Full record

ArticleFrontiers in cell and developmental biology2025

Hypoxia alters the response of ovarian cancer cells to the mitomycin C drug.

Aleksandra Gawrylak, Klaudia Brodaczewska, Roksana Iwanicka-Nowicka, Marta Koblowska, Agnieszka Synowiec, Lubomir Bodnar, Cezary Szczylik, Bogdan Lesyng, Rafał Stec, Claudine Kieda

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Aleksandra GawrylakMilitary Institute of Medicine - National Research Institute, Laboratory of Molecular Oncology and Innovative Therapies, Szaserów, Warsaw, Poland.
Klaudia BrodaczewskaMilitary Institute of Medicine - National Research Institute, Laboratory of Molecular Oncology and Innovative Therapies, Szaserów, Warsaw, Poland.
Roksana Iwanicka-NowickaLaboratory of Systems Biology, Faculty of Biology, University of Warsaw, Warsaw, Poland.
Marta KoblowskaLaboratory of Systems Biology, Faculty of Biology, University of Warsaw, Warsaw, Poland.
Agnieszka SynowiecMilitary Institute of Medicine - National Research Institute, Laboratory of Molecular Oncology and Innovative Therapies, Szaserów, Warsaw, Poland.
Lubomir BodnarFaculty of Medical and Health Sciences, Siedlce University of Natural Sciences and Humanities, Siedlce, Poland.
Cezary SzczylikDepartment of Oncology, Centre of Postgraduate Medical Education, European Health Centre, Otwock, Poland.
Bogdan LesyngDivision of Biophysics and Center for Machine Learning, Faculty of Physics, University of Warsaw, Warsaw, Poland.
Rafał StecOncology Department, Medical University of Warsaw, Warsaw, Poland.
Claudine KiedaMilitary Institute of Medicine - National Research Institute, Laboratory of Molecular Oncology and Innovative Therapies, Szaserów, Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Discrepancies between preclinical tests and clinical results raise serious concerns about the appropriateness of the current methodologies. In particular, cell biology approaches neglect fundamental physical parameters despite their relevance to Methods: To evaluate the effects of MMC and oxygen tension (pO Results: Under normoxic conditions, MMC mostly affected several pathways associated with ribosome-related processes, whereas under hypoxic conditions, it induced modifications in the extracellular matrix (ECM). The most significantly upregulated gene in response to hypoxia-MMC treatment was Conclusion: Hypoxia modulated the effects of MMC on OC cells and identified genes that may serve as promising targets to enhance the effectiveness of MMC treatment.

Indexed as

differential gene expressionhypoxiamitomycin covarian cancerpathway analysistranscriptome

Identifiers

PMID40584967
PMCPMC12202450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.